Microscopic Colitis: Lymphocytic vs Collagenous Colitis — Watery Diarrhea, Normal Scope, and What to Do

1. What Is Microscopic Colitis? LC vs CC Pathophysiology

Microscopic colitis (MC) is a chronic inflammatory bowel condition characterized by chronic, watery, non-bloody diarrhea in the setting of a grossly normal-appearing colon. It encompasses two histologically distinct subtypes — lymphocytic colitis (LC) and collagenous colitis (CC) — both unified by the same clinical picture.

The condition sits in an unusual clinical space: patients are genuinely ill, often severely so, yet their colonoscopy looks unremarkable to the endoscopist. Without biopsy, MC is routinely missed and misclassified as irritable bowel syndrome for years.

Lymphocytic Colitis (LC)

In LC, the defining pathological feature is an excess of intraepithelial lymphocytes (IELs). The diagnostic threshold is >20 IELs per 100 surface epithelial cells, compared to a normal count of fewer than 5. These T-lymphocytes infiltrate the epithelial lining, disrupting tight junctions and impairing the epithelial barrier. The result is increased mucosal permeability and net secretory diarrhea — the colon cannot reabsorb water at its normal rate.

Collagenous Colitis (CC)

CC is defined by a thickened subepithelial collagen band measuring >10 micrometers (normal is 1–3 μm). This fibrotic deposit lies directly beneath the surface epithelium and disrupts normal water transport. CC also shows surface epithelial damage, mixed inflammatory infiltrate in the lamina propria, and IEL counts that are elevated but typically lower than in pure LC.

CC shows a stronger female predominance (female-to-male ratio up to 9:1) and peaks in incidence in women aged 60–70. LC also predominates in women but with a less extreme ratio.

Immune Mechanisms

Both subtypes involve dysregulated mucosal immunity, with luminal antigens (bacteria, drugs, dietary proteins) triggering abnormal T-cell activation in genetically susceptible individuals. Increased production of pro-inflammatory cytokines — TNF-α, interferon-gamma, and IL-15 — drives lymphocyte recruitment and collagen deposition respectively. The HLA-DQ2/DQ8 haplotype, shared with celiac disease, appears with increased frequency in MC patients, suggesting overlapping immune pathways.

2. Drug Triggers: NSAIDs, PPIs, SSRIs, and Statins

One of the most clinically important aspects of MC is that 30–40% of cases are directly drug-induced. Identifying and withdrawing the offending agent is the first and sometimes sufficient therapeutic step — some patients achieve full remission by medication change alone.

NSAIDs — The Leading Culprit

Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin, diclofenac, celecoxib) are the most commonly implicated drug class. NSAIDs increase intestinal permeability, alter prostaglandin-mediated fluid and electrolyte transport, and promote mucosal inflammation. Epidemiological studies show an odds ratio of 3–5 for MC in NSAID users. Symptoms can develop within weeks of starting regular use. Rechallenge studies demonstrate recurrence of diarrhea in the majority of patients who restart NSAIDs after withdrawal-induced remission.

Proton Pump Inhibitors (PPIs)

PPIs (omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole) have a particularly strong association with CC. The proposed mechanisms include alteration of colonic microbiota, increased colonic permeability, and possible direct mucosal effects. Several case-control studies report an odds ratio of 4–8 for CC in PPI users. Because PPIs and NSAIDs are often co-prescribed, disentangling their relative contributions requires careful medication review. Time to onset: typically 6–36 months of continuous PPI use before MC manifests.

SSRIs and SNRIs

Sertraline is the most-studied SSRI trigger, with multiple case series documenting de novo MC after initiation and resolution after withdrawal. Paroxetine, citalopram, and fluoxetine have also been implicated. The mechanism may involve serotonin-driven altered colonic motility and secretion, combined with direct mucosal immune effects. Onset is typically within 3–12 months of starting the antidepressant.

Statins

Simvastatin and other statins have been associated with MC, though the evidence is less robust than for NSAIDs and PPIs. Case reports document resolution after statin withdrawal and recurrence on rechallenge.

Other Implicated Drugs

• Acarbose (diabetes medication) — one of the strongest individual drug associations with CC
• Ranitidine and other H2 blockers — limited but documented association
• Checkpoint inhibitors (cancer immunotherapy, e.g., pembrolizumab) — increasingly recognized cause of MC-pattern colitis
• Carbamazepine and other anticonvulsants
• Ticlopidine (antiplatelet) — high individual risk, rare drug

3. Diagnosis: Biopsy Protocol and Endoscopy Pitfalls

Diagnosing MC requires active clinical suspicion combined with a systematic biopsy protocol. The single most common reason for missed MC is performing colonoscopy without taking biopsies — or taking biopsies from only one segment of the colon.

Who to Suspect

Consider MC in any adult (particularly women over 50) with chronic or intermittent watery, non-bloody diarrhea, especially when:

• The diarrhea is secretory — it persists during fasting or worsens at night
• Stool volumes are large (often >1 liter/day in severe cases)
• Prior colonoscopy was described as "normal" without comment on biopsy results
• The patient is on NSAIDs, PPIs, or SSRIs
• There is a personal or family history of celiac disease or autoimmune conditions
• Standard IBS treatments have failed

Biopsy Protocol — Segment Coverage Is Critical

MC disease distribution is patchy and right-sided. This means:

• Take biopsies from the right colon: cecum, ascending colon, and hepatic flexure. CC in particular can be limited to the proximal colon.
• Also biopsy the left colon: sigmoid colon and descending colon, where LC is often most prominent.
• Minimum 4–6 biopsies from at least two separate segments. A single rectal biopsy is insufficient and will miss the majority of MC cases.
• Biopsies should be placed in separate labeled containers by anatomical location so the pathologist can report segment-specific findings.

Endoscopy Appearance

In most patients, the colonoscopy is visually normal. Occasionally in CC, the endoscopist may note subtle mucosal edema or linear mucosal tears (a phenomenon called "cat scratch colon") — but these findings are non-specific and can occur from the scope itself. The absence of visible inflammation should never be interpreted as ruling out MC.

Ruling Out Concurrent Celiac Disease

Approximately 5% of MC patients have concurrent celiac disease, and some studies report rates as high as 10%. Both conditions can cause chronic secretory diarrhea and can coexist. Any MC patient with an additional malabsorptive pattern (weight loss, iron deficiency, vitamin B12 deficiency) should be tested for celiac with serum tissue transglutaminase IgA and total IgA. If celiac is confirmed, a gluten-free diet is essential — and may itself resolve the MC.

Laboratory Workup

There is no specific blood test for MC. The workup aims to exclude other causes:

• Stool cultures and C. difficile PCR to rule out infection
• Fecal calprotectin (typically elevated in MC, helps distinguish from IBS)
• CBC, CRP, ESR (often normal or mildly elevated in MC)
• Thyroid-stimulating hormone (TSH) — thyroid disease is a co-occurring condition
• tTG-IgA and total IgA for celiac
• Electrolytes and renal function (severe diarrhea causes dehydration and hypokalemia)

4. Treatment: Budesonide, Bismuth, and Biologics for Refractory Disease

MC is highly treatable. The majority of patients achieve clinical remission with first-line therapy, and even refractory cases now have biologic options. Treatment is generally stepped, beginning with drug withdrawal and lifestyle measures before escalating to pharmacotherapy.

Step 1: Drug Withdrawal

For drug-induced MC, withdrawing the causative agent is the essential first step. In some patients — particularly those with NSAID- or PPI-induced MC — drug cessation alone results in complete symptom resolution within 2–4 weeks. This step should always precede or accompany pharmacotherapy. Coordinate medication changes with the patient's primary care physician or prescribing specialist.

Step 2: Lifestyle Modifications

While lifestyle changes alone rarely produce remission, they reduce symptom burden while pharmacotherapy takes effect:

• Avoid caffeine and alcohol (both stimulate colonic secretion)
• Reduce dietary fat during flares
• Rule out lactose intolerance (frequently co-existing)
• Consider low-FODMAP dietary trial (modest evidence)
• Adequate hydration and oral electrolyte repletion

Step 3: Bismuth Subsalicylate

Bismuth subsalicylate (Pepto-Bismol), dosed at 8 tablets per day (262 mg each) in divided doses for 8 weeks, is an evidence-backed treatment for both LC and CC. A landmark uncontrolled trial by Fine and Lee demonstrated clinical and histological improvement in the majority of patients. Bismuth is particularly useful for mild-to-moderate MC or as an alternative when budesonide is unavailable or cost-prohibitive. The mechanism involves binding of luminal toxins, anti-secretory effects, and possible direct anti-inflammatory activity. Stools may turn dark or black — this is expected and harmless.

Step 4: Budesonide — Gold Standard

Oral budesonide (Entocort EC) 9 mg daily for 8 weeks is the most consistently effective treatment for both LC and CC, achieving clinical remission in approximately 85% of patients. Multiple randomized controlled trials support this recommendation, and it is endorsed by the American Gastroenterological Association (AGA), the European Microscopic Colitis Group (EMCG), and the British Society of Gastroenterology (BSG).

Budesonide's advantages over systemic corticosteroids (prednisone) include first-pass hepatic metabolism that limits systemic side effects. However, some patients experience insomnia, mood changes, or glucose elevation, particularly at the 9 mg dose.

Tapering: After initial 8-week induction, taper to 6 mg for 2 weeks, then 3 mg for 2 weeks before stopping. Abrupt discontinuation increases relapse risk.

Maintenance: Up to 80% of patients relapse after budesonide withdrawal. For relapsers, maintenance budesonide 6 mg or 3 mg daily for 6–12 months is appropriate, with the goal of eventual drug-free remission.

Step 5: Cholestyramine

The bile acid sequestrant cholestyramine (4 g three times daily) is useful in patients with suspected bile acid malabsorption contributing to MC, and in those with mild disease or intolerance to other treatments. Response rates are lower than budesonide but it is well-tolerated. Note that cholestyramine can bind other medications — space dosing by at least 2 hours from other drugs.

Step 6: Mesalamine

Mesalamine (5-aminosalicylic acid), while the backbone of ulcerative colitis therapy, has inconsistent evidence in MC. Some trials show modest benefit, particularly in LC. It is generally considered a second-line option or adjunct, not a preferred monotherapy.

Step 7: Immunomodulators

For budesonide-dependent or refractory patients, azathioprine or 6-mercaptopurine have case-series evidence supporting long-term maintenance. Thiopurine metabolite testing (6-TGN levels, TPMT enzyme activity) should guide dosing.

Step 8: Biologics for Refractory MC

Vedolizumab (Entyvio), the gut-selective integrin inhibitor approved for ulcerative colitis and Crohn's disease, has emerging evidence in refractory MC. Case series and small prospective studies report clinical remission in 60–80% of treatment-refractory patients. Anti-TNF agents (infliximab, adalimumab) have also been used in refractory cases, though evidence is primarily from case reports. Biologic therapy for MC remains off-label and is reserved for patients who have failed budesonide, bismuth, and immunomodulators.

5. Autoimmune Associations and Long-Term Outlook

Microscopic colitis does not exist in isolation. It sits within a broader constellation of autoimmune conditions, and recognizing co-existing disease is essential for comprehensive management and patient counseling.

Celiac Disease

The association between MC and celiac disease is bidirectional and clinically significant. Approximately 5% of MC patients have confirmed celiac disease on duodenal biopsy, and conversely, patients with celiac have a 50–70 times higher relative risk of developing MC compared to the general population. Both conditions share HLA-DQ2/DQ8 genetic risk, similar demographic profiles (female, middle-aged to older), and immune mechanisms involving abnormal T-cell responses to luminal antigens. In patients with MC and concurrent celiac, a strict gluten-free diet is mandatory and may independently improve colitis.

Thyroid Disease

Autoimmune thyroid conditions — Hashimoto's thyroiditis and Graves' disease — occur with excess frequency in MC populations. Studies from Scandinavia (where MC incidence data are most robust) show a 2–4 fold increased prevalence of thyroid autoimmunity in MC patients versus age-matched controls. Routine TSH screening is reasonable at MC diagnosis, particularly in older women who are already at elevated baseline thyroid disease risk.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) co-occurs with MC at higher-than-expected rates. This is clinically important because NSAIDs — commonly used in RA — are a major MC trigger. Patients with RA who develop diarrhea require evaluation for drug-induced MC, and ongoing NSAID use should be re-evaluated in confirmed MC.

Other Autoimmune Conditions

• Sjögren's syndrome — documented excess co-occurrence
• Type 1 diabetes — associated in some registry studies
• Psoriasis — case series and registry associations
• Primary biliary cholangitis — limited case reports

Cancer Risk — No Increased Risk

Unlike ulcerative colitis and Crohn's disease, microscopic colitis is not associated with an increased risk of colorectal cancer. Multiple population-based studies from Sweden, Denmark, and the United States consistently show no excess colorectal cancer incidence in MC cohorts. This is reassuring and should be communicated clearly to patients who fear that their chronic colitis carries the same cancer implications as other IBD subtypes. Routine MC-specific cancer surveillance colonoscopy is therefore not indicated.

Relapse Rates and Long-Term Course

MC typically follows a relapsing-remitting course. Key data points:

• Up to 80% of patients relapse after stopping budesonide, usually within 3 months of withdrawal
• Approximately 20–30% of patients achieve spontaneous remission, particularly those with mild disease or LC (more than CC)
• Long-term budesonide maintenance at the lowest effective dose (3–6 mg) controls most relapsers
• Quality of life is significantly impaired during active disease but normalizes in remission
• Progression between subtypes (LC converting to CC or vice versa) occurs rarely (<5% of cases)
• MC does not progress to Crohn's disease or ulcerative colitis

Supportive Products for Microscopic Colitis

Pharmacotherapy requires a prescription, but these over-the-counter options are part of the MC management toolkit. Always discuss with your gastroenterologist before starting.